Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 2023 Nov 18;72(12):4471. doi: 10.1007/s00262-023-03575-4

Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma

Lisa May Ling Tachiki 1,3,✉, Daniel S Hippe 3, Karly Williams Silva 1,3, Evan Thomas Hall 1,3, William McCamy 1, Dane Fritzsche 3, Andrea Perdue 1,3, Julia Majovski 1,3, Thomas Pulliam 2,3, Daniel A Goldstein 4, Joshua Veatch 1,3, Joel Ho 1,3, Paul T Nghiem 2,3, John A Thompson 1,3, Shailender Bhatia 1,3,✉
PMCID: PMC10700449  PMID: 37979010

Correction to: Cancer Immunology, Immunotherapy (2023) 72:3839–3850 10.1007/s00262-023-03539-8

The original version of this article unfortunately contained a mistake. The corrected detail is provided below:

In discussion section, 6th sentence of the 10th paragraph which previously read:

In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD.

Should read:

In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Lisa May Ling Tachiki, Email: ltachiki@uw.edu.

Shailender Bhatia, Email: sbhatia@uw.edu.

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES